This study aims to describe the treatment patterns and clinical outcomes of treatment with eltrombopag in primary immune thrombocytopenia (ITP) patients treated with prior corticosteroid therapy.
This study will use secondary data provided by health care professionals (HCPs) for a sample of primary ITP patients, and primary data from a structured HCP survey. Data will be collected from HCPs working in various clinical centers across the United States (US), United Kingdom (UK), and Germany.
A licensed HCP (e.g., internal medicine specialist, hematologist, hematologist-oncologist or immunologist etc.) involved in the management of adult patients with primary ITP.
Actively involved in treatment decision-making for primary ITP patients at the time of the study.
Have a minimum of 3 years of experience managing patients with primary ITP.
Currently, managing an average of at least 2 adult primary ITP patients per month, including those treated with eltrombopag.
Currently employed by a pharmaceutical company or regulatory authority involved in the approval or marketing of treatments for primary ITP.
Unable to provide data for patients who meet the study's inclusion criteria.
Not currently managing patients with primary ITP or are not involved in treatment decisions for these patients.
Adult patients diagnosed with primary ITP who were treated with eltrombopag following corticosteroid treatment.
Cohort
Retrospective
Not listed
Number and Percentage of Patients Achieving an Initial Platelet Response Within 12 Weeks of Start of Treatment
Initial platelet response is defined as a platelet count ≥50 × 10\^9/L.
Number and Percentage of Patients Achieving an Initial Complete Platelet Response Within 12 Weeks of Start of Treatment
Complete platelet response is defined as a platelet count of ≥100 × 10\^9/L.
Number and Percentage of Patients Achieving a Partial Platelet Response Within 12 Weeks of Start of Treatment
Partial platelet response is defined as a platelet count of ≥30 × 10\^9/L.
Number and Percentage of Patients With No or Suboptimal Platelet Response Within 12 Weeks of Start of Treatment
No or suboptimal platelet response is defined as a platelet count of \<30 × 10\^9/L.
Number and Percentage of Patients Achieving Clinically Meaningful Platelet Response Thresholds Within 12 Weeks of Start of Treatment
Clinically meaningful platelet response thresholds as indicated by a platelet count increase from a pretreatment value \<30 × 10\^9/L, and/or documentation of improvement in clinical symptoms such as bleeding.
Click on the lead sponsor to view all of their trials.
